TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.

IF 2 4区医学 Q3 ONCOLOGY

Tumori Pub Date : 2023-10-01 Epub Date: 2023-01-06 DOI:10.1177/03008916221147944

Beatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, Maria Antista, Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, Veronica Conca, Marco Maria Germani, Leonardo Provenzano, Andrea Spagnoletti, Alberto Giovanni Leone, Federico Cucchiara, Filippo Pietrantonio, Marzia Del Re, Romano Danesi, Gianluca Masi, Chiara Cremolini, Roberto Moretto

{"title":"TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.","authors":"Beatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, Maria Antista, Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, Veronica Conca, Marco Maria Germani, Leonardo Provenzano, Andrea Spagnoletti, Alberto Giovanni Leone, Federico Cucchiara, Filippo Pietrantonio, Marzia Del Re, Romano Danesi, Gianluca Masi, Chiara Cremolini, Roberto Moretto","doi":"10.1177/03008916221147944","DOIUrl":null,"url":null,"abstract":"Background: Trifluridine/tipiracil and regorafenib are indicated for metastatic colorectal cancer (mCRC) patients' refractory to standard chemotherapy. No prognostic or predictive biomarkers are available for these agents.Methods: We assessed messenger ribonucleic acid (mRNA) expression of four biomarkers implicated in the mechanism of action of trifluridine/tipiracil (TK-1 and TP) and regorafenib (Ang-2 and Tie-2) in baseline plasma-derived microvesicles of chemo-refractory mCRC patients treated with these agents (trifluridine/tipiracil cohort and regorafenib cohort), to explore their prognostic and predictive role.Results: Baseline characteristics of the two cohorts were not different. Ang-2 mRNA was not detectable. Only TK-1 expression measured as a continuous variable was associated with progression-free survival (HR=1.09, 95%CI: 0.99-1.21; p=0.07) and overall survival (HR=1.11, 95%CI: 1.00-1.22; p=0.04), confirmed at multivariate analysis for progression-free survival (p=0.02) with a positive trend for overall survival (p=0.08). Baseline mRNA levels of TK-1, TP and Tie-2 were not predictive of trifluridine/tipiracil and regorafenib benefit.Conclusion: Baseline mRNA levels of TK-1, TP and Tie-2 on plasma-derived microvesicles were not predictive of trifluridine/tipiracil and regorafenib benefit. Future studies should analyze the early modulation of these biomarkers to assess their potential predictive role.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"481-489"},"PeriodicalIF":2.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916221147944","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Trifluridine/tipiracil and regorafenib are indicated for metastatic colorectal cancer (mCRC) patients' refractory to standard chemotherapy. No prognostic or predictive biomarkers are available for these agents.

Methods: We assessed messenger ribonucleic acid (mRNA) expression of four biomarkers implicated in the mechanism of action of trifluridine/tipiracil (TK-1 and TP) and regorafenib (Ang-2 and Tie-2) in baseline plasma-derived microvesicles of chemo-refractory mCRC patients treated with these agents (trifluridine/tipiracil cohort and regorafenib cohort), to explore their prognostic and predictive role.

Results: Baseline characteristics of the two cohorts were not different. Ang-2 mRNA was not detectable. Only TK-1 expression measured as a continuous variable was associated with progression-free survival (HR=1.09, 95%CI: 0.99-1.21; p=0.07) and overall survival (HR=1.11, 95%CI: 1.00-1.22; p=0.04), confirmed at multivariate analysis for progression-free survival (p=0.02) with a positive trend for overall survival (p=0.08). Baseline mRNA levels of TK-1, TP and Tie-2 were not predictive of trifluridine/tipiracil and regorafenib benefit.

Conclusion: Baseline mRNA levels of TK-1, TP and Tie-2 on plasma-derived microvesicles were not predictive of trifluridine/tipiracil and regorafenib benefit. Future studies should analyze the early modulation of these biomarkers to assess their potential predictive role.

查看原文本刊更多论文

TK-1、TP、Ang-2和Tie-2 mRNA在化疗性转移性癌症患者血浆源性微泡中的表达。

背景：三氟啶/替吡拉西和瑞戈非尼适用于转移性癌症（mCRC）患者对标准化疗的难治性。没有可用于这些药物的预后或预测性生物标志物。方法：我们评估了四种与三氟吡啶/替吡拉西（TK-1和TP）和瑞戈非尼（Ang-2和Tie-2）作用机制有关的生物标志物在用这些药物治疗的化疗难治性mCRC患者的基线血浆来源的微泡中的信使核糖核酸（mRNA）表达（三氟吡啶/tipiracil队列和瑞戈芬尼队列），探讨其预后和预测作用。结果：两组患者的基线特征没有差异。Ang-2 mRNA未检测到。只有作为连续变量测量的TK-1表达与无进展生存期（HR=1.09，95%CI:0.99-1.21；p=0.07）和总生存期（HR=1.11，95%CI:1.00-1.22；p=0.04）相关，无进展生存率的多变量分析证实了这一点（p=0.02），总生存率呈阳性趋势（p=0.08），TP和Tie-2不能预测三氟吡啶/替吡拉西和瑞戈非尼的益处。结论：血浆来源的微泡上TK-1、TP和Tie-2的基线mRNA水平不能预测三氟吡啶/替吡拉西和瑞戈非尼的益处。未来的研究应该分析这些生物标志物的早期调节，以评估其潜在的预测作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.